Bioequivalence Study of Torrent Pharmaceutical Limited's Pantoprazole Sodium 40 mg Delayed Release Tablets Under Fed Conditions

A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets of Torrent Pharmaceutical Limited., India and Protonix® (Pantoprazole Sodium) 40 mg Delayed Release Tablets of Wyeth Pharmaceuticals Inc, in Healthy Human Adult Subjects, Under Fed Conditions

Objective:

To compare the single dose bioavailability of Torrent's Pantoprazole Sodium Delayed - Release Tablets 1 × 40 mg and PROTONIX® (Pantoprazole Sodium) Delayed - Release Tablets 1 × 40 mg of Wyeth Pharmaceutical Inc. Dosing periods were separated by a washout period of at least 7 days.

Study Design:

randomized, open label, two treatment, two period, two sequence, single dose, crossover study in healthy human adult subjects

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Torrent's Pantoprazole Sodium Delayed - Release Tablets

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

Study Locations

• India
  • Karnataka,
    • Bangalore,, Karnataka,, India
      • Lotus Labs Pvt. Ltd.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy human adult subjects between 18-55 years of age (inclusive), having a body mass index (BMI) between 18 and 27 kg/m2.
• Subjects who have no evidence of underlying disease during screening history and whose physical examination is performed within 21 days prior to commencement of the study.
• Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
• Informed consent given in written form according to section 11.3 of the protocol.

• Female Subjects:

  1. Of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
  2. Postmenopausal for at least 1 year.
  3. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).

Exclusion Criteria:

• History or presence of significant:

  1. Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
  2. Alcohol dependence, alcohol abuse or drug abuse within past one year.
  3. Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products.
  4. History of difficulty in swallowing tablet / capsule.
  5. Clinically significant illness within 4 weeks before the start of the study
  6. Asthma, urticaria or other allergic type reactions after taking any medication.
  7. Positive urine drug screening, HIV, Hepatitis B & C tests.
  8. Any history of hypersensitivity to Pantoprazole Sodium.
  9. Existence of any surgical or medical condition, which, in the judgment of clinical investigator might interfere with the pharmacokinetics of the drug or likely to compromise the safety of the subject.
  10. Inability to communicate or co-operate with the investigator due to language problem, attitude, poor mental development / impaired cerebral function.
• Subject who has participated in any other clinical trial involving drug administration and collection of blood samples or has donated blood in the preceding 12 weeks prior to the start of the study.

• Subjects who have:

  1. Systolic blood pressure less than 90 mm of Hg or more than 150 mm of Hg.
  2. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg.
  3. Minor deviations (2-4 mm Hg) at check-in may be acceptable at the discretion of the physician /investigator.
  4. Pulse rate below 50/minute or above 105/minute.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description
bioequivalence based on Composite of Pharmacokinetics	bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax.

Collaborators and Investigators

• Sponsor: Torrent Pharmaceuticals Limited

Study record dates

Study Registration Dates

• First Submitted: August 10, 2011
• First Submitted That Met QC Criteria: August 16, 2011
• First Posted (ESTIMATE): August 17, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): August 17, 2011
• Last Update Submitted That Met QC Criteria: August 16, 2011
• Last Verified: August 1, 2011

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nutrition Disorders; Malnutrition; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Gastrointestinal Agents; Anti-Ulcer Agents; Proton Pump Inhibitors; Pantoprazole
• Other Study ID Numbers: 1201/07